RhumbLine Advisers’s Mirum Pharmaceuticals MIRM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.29M | Buy |
64,593
+9,159
| +17% | +$466K | ﹤0.01% | 1626 |
|
|
2025
Q1 | $2.5M | Buy |
55,434
+2,321
| +4% | +$105K | ﹤0.01% | 1702 |
|
|
2024
Q4 | $2.2M | Buy |
53,113
+1,236
| +2% | +$51.1K | ﹤0.01% | 1841 |
|
|
2024
Q3 | $2.02M | Sell |
51,877
-1,039
| -2% | -$40.5K | ﹤0.01% | 1908 |
|
|
2024
Q2 | $1.81M | Buy |
52,916
+17,279
| +48% | +$591K | ﹤0.01% | 1939 |
|
|
2024
Q1 | $895K | Sell |
35,637
-187
| -0.5% | -$4.7K | ﹤0.01% | 2312 |
|
|
2023
Q4 | $1.06M | Sell |
35,824
-320
| -0.9% | -$9.45K | ﹤0.01% | 2216 |
|
|
2023
Q3 | $1.14M | Buy |
36,144
+1,867
| +5% | +$59K | ﹤0.01% | 2128 |
|
|
2023
Q2 | $887K | Buy |
34,277
+10,201
| +42% | +$264K | ﹤0.01% | 2359 |
|
|
2023
Q1 | $578K | Buy |
24,076
+1,261
| +6% | +$30.3K | ﹤0.01% | 2376 |
|
|
2022
Q4 | $445K | Buy |
22,815
+724
| +3% | +$14.1K | ﹤0.01% | 2522 |
|
|
2022
Q3 | $464K | Buy |
22,091
+3,747
| +20% | +$78.7K | ﹤0.01% | 2531 |
|
|
2022
Q2 | $357K | Buy |
+18,344
| New | +$357K | ﹤0.01% | 2665 |
|